The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 462,021 shares of Sanara MedTech Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: 462,021 shares of Sanara MedTech Inc. common stock, representing 5.0% of the class.
  • Shared voting power: Both reporting persons report shared voting power over 462,019 shares.
  • Shared dispositive power: Both reporting persons report shared dispositive power over 462,021 shares.
  • Sole voting and dispositive power: Both reporting persons report 0.00 shares held with sole voting or sole dispositive power.
  • Triggering event date: The date of event requiring this filing is stated as September 30, 2026.
  • Filing signed: Ameen Soetan, identified as attorney-in-fact for both entities, signed the filing on October 8, 2026.

Goldman Sachs Discloses 5.0% Position in Sanara MedTech Common Stock

According to the filing, The Goldman Sachs Group, Inc. (GS Group) and its subsidiary Goldman Sachs & Co. LLC jointly submitted a Schedule 13G reporting beneficial ownership of Sanara MedTech Inc. (CUSIP 79957L100) common stock, $0.001 par value. The event triggering the filing occurred on September 30, 2026, and the statement was signed on October 8, 2026. Sanara MedTech Inc. is listed with principal executive offices at 1200 Summit Avenue, Suite 414, Fort Worth, Texas 76102.

The filing discloses that both GS Group and Goldman Sachs & Co. LLC each report aggregate beneficial ownership of 462,021 shares, equaling 5.0% of the class. Neither entity holds sole voting or sole dispositive power over any shares; instead, shared voting power is reported at 462,019 shares and shared dispositive power at 462,021 shares for each reporting person. According to the filing, GS Group is a Delaware holding company, while Goldman Sachs & Co. LLC is organized in New York and is classified as a broker-dealer, investment adviser, and other entity.

Exhibit 99.2 of the filing states that the securities "are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC, a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940," and that Goldman Sachs & Co. LLC is a subsidiary of GS Group. Exhibit 99.3 further notes that the filing "reflects the securities beneficially owned by certain operating units (collectively, the 'Goldman Sachs Reporting Units')" and that those units "disclaim beneficial ownership of the securities beneficially owned by (i) any client accounts with respect to which the Goldman Sachs Reporting Units or their employees have voting or investment discretion or both" and certain other investment entities.

What Was Disclosed

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly disclosed beneficial ownership of 462,021 shares, or 5.0%, of Sanara MedTech Inc. common stock as of September 30, 2026, with all voting and dispositive power held on a shared basis.